Loading
A phase 3 trial of Avelumab, Talazoparib, Pemetrexed in ovarian cancer, run by Pfizer, active and no longer recruiting.
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing is a phase 3 interventional study registered as NCT05059522 by Pfizer, with 77 participants enrolled, started 2021-09-29 and due to reach its primary completion in 2026-12-31. Interventions recorded: Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib. Conditions listed: Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer. No results are recorded here; the registry entry is the source.
Shares Axitinib, Pfizer (incl. Seagen).
Shares Avelumab, Pfizer (incl. Seagen), Immune checkpoint inhibitors.
Shares Avelumab, Immune checkpoint inhibitors.
Shares Axitinib, Immune checkpoint inhibitors.
Shares Avelumab, Immune checkpoint inhibitors.
Shares Avelumab, Immune checkpoint inhibitors.
Shares Avelumab, Immune checkpoint inhibitors.
Shares Avelumab, Immune checkpoint inhibitors.